Molecular Profiles Invests in Hot Melt Extrusion Technology
Molecular Profiles expands technology with GMP hot melt extrusion.
Molecular Profiles, a UK-based pharmaceutical development and manufacturing services provider, has invested in GMP hot melt extrusion (HME) technology along with other milling equipment. The expansion is part of a wider project focusing on enabling technologies to accelerate formulation development, particularly for complex molecules that are difficult to progress.
Rob Harris, chief technical officer at Molecular Profiles, said in a press statement that expanding the company’s in-house equipment would complement its expertise by bringing on-stream a diverse range of enabling technologies to assist drug developers in developing challenging compounds. According to Harris, the new enabling technologies division forms the backbone of the company’s early formulation development services, which primarily specialize in screening formulation options for challenging compounds, developing effective formulations, and finding solutions to meet clients’ product development requirements.
This investment marked a significant venture for Molecular Profiles. The company opened its new clinical production site in July 2013 following a successful inspection from the UK Medicines and Healthcare products Regulatory Agency (MHRA).
Molecular Profiles manufactures a range of dosage forms for clinical trials spanning solids, liquids, semi-solids and inhaled products, including potent compounds.
Source: Molecular Profiles
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
